口服避孕药、激素替代治疗与卒中风险
基于英国生物样本库257194名1939至1970年间出生女性的数据,采用Cox回归模型分析自我报告的口服避孕药和激素替代治疗使用与卒中风险的关联。口服避孕药使用第一年任何类型卒中事件率升高(HR 2.49),激素替代治疗使用第一年任何类型卒中风险升高(HR 2.12),且缺血性卒中和蛛网膜下腔出血风险亦升高。
要点
- 口服避孕药使用第一年任何类型卒中风险升高(HR 2.49,95%CI 1.44-4.30),其余使用年份风险与非使用者相当。
- 激素替代治疗使用第一年任何类型卒中风险升高(HR 2.12,95%CI 1.66-2.70),缺血性卒中(HR 1.93)和蛛网膜下腔出血(HR 2.17)风险亦升高。
- 激素替代治疗其余使用年份任何类型卒中风险仍升高(HR 1.18),停药后风险亦升高(HR 1.16)。
核心结论
- 口服避孕药和激素替代治疗与卒中风险升高相关,尤其是使用第一年,可能源于止血平衡的即时改变。
- 本研究提供了激素暴露对卒中风险影响的新见解,不仅显示总体风险,还显示治疗初期效应更为明显。
研究设计与样本
- 研究纳入英国生物样本库中257194名1939至1970年间出生的女性。
- 暴露为自我报告的口服避孕药和激素替代治疗使用,以时变变量在Cox回归模型中分析。
- 结局包括任何类型卒中、缺血性卒中、脑出血和蛛网膜下腔出血。
主要发现
- 口服避孕药使用第一年任何类型卒中事件率升高(HR 2.49,95%CI 1.44-4.30),其余使用年份风险与非使用者相当(HR 1.00,95%CI 0.86-1.14)。
- 激素替代治疗使用第一年任何类型卒中风险升高(HR 2.12,95%CI 1.66-2.70),缺血性卒中风险升高(HR 1.93,95%CI 1.05-3.57),蛛网膜下腔出血风险升高(HR 2.17,95%CI 1.25-3.78)。
- 激素替代治疗其余使用年份任何类型卒中风险仍升高(HR 1.18,95%CI 1.05-1.31),停药后风险亦升高(HR 1.16,95%CI 1.02-1.32)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Millions of women worldwide use exogenous hormones as oral contraceptives or hormone replacement therapy. Still, time-dependent and long-term consequences of exogenous hormones on stroke risk remains unclear. METHODS: We examined the association between self-reported oral contraceptive and hormone replacement therapy use and stroke risk in 257 194 women from the UK Biobank, born between 1939 and 1970. Outcomes included any type of stroke, ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Exposures were analyzed as time-varying variables in Cox regression models. RESULTS: During first year of oral contraceptive use, an increased event rate of any stroke was observed (hazard ratio [HR], 2.49 [95% CI, 1.44-4.30]), while the hazards were found to be comparable during remaining years of use (HR, 1.00 [95% CI, 0.86-1.14]), compared with nonusers. Similarly, first year of hormone replacement therapy use was associated with higher hazard rates of any stroke (HR, 2.12 [95% CI, 1.66-2.70]), as well as cause-specific stroke, including ischemic stroke (HR, 1.93 [95% CI, 1.05-3.57]) and subarachnoid hemorrhage (HR, 2.17 [95% CI, 1.25-3.78]), which remained increased for any stroke during remaining years of use (HR, 1.18 [95% CI, 1.05-1.31]), and after discontinuation (HR, 1.16 [95% CI, 1.02-1.32]). CONCLUSIONS: Oral contraceptive use and hormone replacement therapy were associated with an increased risk of stroke, especially during the first year of use, possibly due to immediate changes in hemostatic balance. This study provides new insights on the effects of hormone exposure on stroke risk and provide evidence of not only an overall risk but also a pronounced effects seen in the beginning of treatment.
引用
- Johansson T, Fowler P, Ek WE, et al. Oral Contraceptives, Hormone Replacement Therapy, and Stroke Risk. Stroke. 2022. PMID: 35735009. doi:10.1161/STROKEAHA.121.038659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。